menu
    • menu
    [{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Tagraxofusp","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Stemline Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Stemline Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Tagraxofusp","moa":"EEF2","graph1":"Oncology","graph2":"Approved","graph3":"Stemline Therapeutics","amount2":0.68000000000000005,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.68000000000000005,"dosageForm":"","sponsorNew":"Stemline Therapeutics \/ Menarini ","highestDevelopmentStatusID":"12","companyTruncated":"Stemline Therapeutics \/ Menarini "},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Tagraxofusp","moa":"EEF2","graph1":"Oncology","graph2":"Approved","graph3":"Stemline Therapeutics","amount2":0.68000000000000005,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.68000000000000005,"dosageForm":"","sponsorNew":"Stemline Therapeutics \/ Menarini","highestDevelopmentStatusID":"12","companyTruncated":"Stemline Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Elacestrant","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stemline Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Stemline Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Stemline Therapeutics","amount2":0.51000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Stemline Therapeutics \/ Stemline Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Stemline Therapeutics \/ Stemline Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Stemline Therapeutics

    Menu

    Stemline Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Stemline Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Stemline Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Insilico Medicine

                            Deal Size : $512.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Menarini Group Signs Exclusive License for KAT6 Inhibitor for Breast Cancer

                            Details : Stemline will have global rights to develop a novel KAT6A inhibitor designed using Insilico’s AI platform, targeting hormone-sensitive cancers and other oncology indications.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $12.0 million

                            January 04, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Insilico Medicine

                            Deal Size : $512.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Stemline Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Stemline Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elacestrant

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Stemline Therapeutics, a Subsidiary of Menarini Group, Receives U.S. FDA Approval for Orserdu™ (elacestrant)...

                            Details : Orserdu (elacestrant) is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). It inhibits 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway.

                            Brand Name : Orserdu

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 30, 2023

                            Lead Product(s) : Elacestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Stemline Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Stemline Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Menarini

                            Deal Size : $677.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Menarini Group Completes Acquisition of Stemline Therapeutics

                            Details : Acquisition establishes Menarini’s presence in the U.S. biopharmaceutical oncology market. Menarini will support further development of Stemline’s ELZONRIS and enable global expansion by leveraging its commercial infrastructure in Europe and other ex...

                            Brand Name : Elzonris

                            Molecule Type : Large molecule

                            Upfront Cash : $677.0 million

                            June 10, 2020

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Menarini

                            Deal Size : $677.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Stemline Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Stemline Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Menarini

                            Deal Size : $677.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

                            Details : With the support of Menarini’s infrastructure, Stemline will continue its efforts to develop new applications of ELZONRIS to meet unmet needs of patients with difficult to treat diseases and cancers.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $677.0 million

                            May 04, 2020

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Menarini

                            Deal Size : $677.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Stemline Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Stemline Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Comm...

                            Details : A Phase 1/2 trial of ELZONRIS in combination with other agents in patients with relapsed/refractory AML, treatment-naive AML unfit for chemotherapy, and high-risk myelodysplastic syndrome (MDS) is currently enrolling patients.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 13, 2020

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth